In humans, circulating GDF15 levels were found to change according to the liver fat content (Galuppo et al. 2022) and were significantly associated with the risk of advanced fibrosis but not with the risk of MASH (Koo & Guan 2018). This evidence concerns the gene GDF15 and metabolic dysfunction-associated steatohepatitis.